MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

2017 International Congress

June 4-8, 2017. Vancouver, BC.

View by Title View Sessions
View by Date
Jump to:  View All • a b c d e f g h i j k l [m] n o p q r s t u v w x y z
  • Management of fragility fractures in Parkinson’s Disease (PD)

    G. Alg, A. Chatterjee (Reading, United Kingdom)

  • Management of parkinsonism in primary care.

    A. Planas-Ballve, M. Muñoz, K. Beyer, L. Ispierto, D. Vilas, A.M. Crespo, L. Abraira, T. Canento, R. Álvarez (Badalona, Spain)

  • Managing severe dyskinesia in Parkinson’s Disease using 24-hour Levodopa/Carbidopa Intestinal Gel Infusion

    B. Cruse, D. Tsui, J. Griffith, H. Morales-Briceno, F. Chang, A. Ha, S. Kim, N. Wolfe, V. Kwan, N. Mahant, V. Fung (Westmead, Australia)

  • MANF protects dopamine neurons and locomotion defect from Neurotoxin/Human alpha-synuclein-induced progressive Parkinson’s disease models in C.elegans.

    Z. Zhang (Shanghai, China)

  • Manifestations of restless legs syndrome and its influence on the clinical course of associated migraine

    M. Sanoeva (Bukhara, Uzbekistan)

  • Manual and Verbal guidance during the balance training based in virtual reality is essential for therapeutic results in people with Parkinson’s disease: a randomized clinical trial

    M.E. Pimentel Piemonte, A. Falconi, M. D"Alencar, E. Okamoto (Sao Paulo, Brazil)

  • Marc Chagall’s L’homme à La Tète Renversée (Man with His Head Thrown Back) – An Artistic Depiction of Severe Retrocollis in Neurodegeneration with Brain Iron Accumulation

    L. Oliveira, M. Caeira, F. Germiniani, H. Teive, T. Roza, C.H. Camargo (Curitiba, Brazil)

  • Marked occipital hypometabolism on FDG-PET in patients with idiopathic RBD may predict Parkinson’s disease

    K. Kashihara, M. Kitayama, T. Hamaguchi (Okayama, Japan)

  • Maximising decrease in Dopaminergic drugs and increase in ON time following Bilateral STN DBS using constant current for Advanced Parkinsons Disease

    S. SANYAL (CALCUTTA (KOLKATA), India)

  • MDS prodromal PD research criteria validation in two independent prospective cohorts

    A. Pilotto, S. Heinzel, U. Suenkel, S. Lerche, K. Brockmann, b. Roeben, E. Schaeffer, i. Wurster, R. Yilmaz, I. Liepelt-Scarfone, A. von Thaler, F. Metzger, g. Eschweiler, R. Postuma, W. Maetzler, D. Berg (Tuebingen, Germany)

  • Measuring temporal irregularity in spiral drawings of patients with Parkinson’s disease

    S. Aghanavesi, M. Memedi, J. Westin (Borlange, Sweden)

  • Mechanisms of sub-anesthetic ketamine infusions to reduce L-DOPA-induced dyskinesia: effects on striatal mTOR signaling and beta band oscillations in striatum and motor cortex

    M. Bartlett, A. Flores, T. Ye, H. Dollish, K. Doyle, S. Cowen, S. Sherman, T. Falk (Tucson, AZ, USA)

  • Medical Treatment Termination in Parkinson’s Disease Patients after Hepad Therapy: A Case Series

    D.H. Kim, D.H. Kim, J.J. Choi, B.J. Park (Daejeon, Republic of Korea)

  • Medically refractory paroxysmal kinesigenic dyskinesia in a 7 year old with a novel PRRT2 mutation

    K. Chillag, E. Chillag (Wyoming, MI, USA)

  • Medication optimization in Parkinson’s disease patients with ON-state freezing using objective gait assessments

    T. Virmani (Little Rock, AR, USA)

  • Mesencephalic astrocyte-derived neurotrophic factor alleviated 6-OHDA-induced cell damage via ROS-AMPK/mTOR mediated autophagic inhibition

    J. Zhang, Q. Cai, M. Jiang, Y. Liu, H. Gu, J. Guo, H. Sun, J. Fang (Shanghai, China)

  • Mesencephalic astrocyte-derived neurotrophic factor reduces cell apoptosis via upregulating HSP70 in SHSY-5Y cells

    H. Sun, M. Jiang, J. Zhang, L. Feng, Y. Liu, Z. Nie, J. Fang, L. Jin (Shanghai, China)

  • Meta-analysis of mortality following Subthalamic and Pallidal deep brain stimulation for patients with Parkinson’s disease

    A. Negida (Zagazig, El-Sharkia, Egypt)

  • Meta-analysis of the interaction between HLA-DRB1 and smoking with Parkinson’s disease

    Y.-H. Chuang, P.-C. Lee, A. Elbaz, B. Ritz (LA, CA, USA)

  • Metabolic changes following transcranial magnetic resonance-guided focused ultrasound subthalamotomy

    R. Rodriguez-Rojas, R. Martinez-Fernandez, J. Pineda-Pardo, C. Sanchez-Catasus, M. del Alamo, J. Obeso (Mostoles, Spain)

  • Metabolic pattern of acute hemichorea associated with contralateral carotid stenosis

    L. Savsek, A. Andlovic, N. Ozimic, L. Jensterle, P. Tomse, M. Grmek, J. Pretnar Oblak, Z. Pirtosek, M. Trost, M. Kojovic (Celje, Slovenia)

  • Metabolic syndrome: Its link with motor function of Parkinson’s disease (PD)

    H. Chan, Y. Cheung, D. Chau, V. Lo, C. Woo, S. Tse, T. Fung, W. Fong (Hong Kong, Hong Kong)

  • Metabolomic biomarkers strongly differentiate PD from healthy controls (HCs) in BioFIND study* specimens

    P. LeWitt, J. Li, M. Lu, K.-H. Wu, Y. Zhou, I. Datta, L. Guo, B. Investigators (West Bloomfield, MI, USA)

  • Metabolomics study in a group of Parkinson’s disease patients from Northern India

    G.N. Babu, M. Gupta, V.K. Paliwal, S. Singh, R. Roy (Lucknow, India)

  • Middle cerebellar peduncle width in multiple system atrophy

    F. Krismer, S. Bajaj, G. Wenning, C. Scherfler, W. Poewe, M. Schocke, A. Hussl, K. Seppi (Innsbruck, Austria)

  • Mild cognitive impairment in newly diagnosed Parkinson’s disease: a three year follow up

    R. Lawson, A. Yarnall, G. Duncan, D. Breen, T. Khoo, C. Williams-Gray, R. Barker, D. Burn (Newcastle Upon Tyne, United Kingdom)

  • Mindfulness for People with Parkinson’s: Emotional Well Being, Social Support and Group Effect

    B. Pickut, S. Woolner, R. Nyenhuis, D. Nyenhuis (Grand Rapids, MI, USA)

  • Minor hallucinations in Parkinson’s disease: neuropshycological and neurophysiological correlates in a representative sample of non-demented patients.

    J. Pagonabarraga, J. Marin-Lahoz, A. Horta, H. Bejr-Kasem, M. Cornella, J. Pérez-Pérez, S. Martinez-Horta, J. Kulisevsky (Barcelona, Spain)

  • Mirror dysonia in writer`s aramp: a study with advanced multi-channel micro-electrode recording EMG system

    V. Rama Raju, R. Borgohain, R. Kandadai (Hderabad, IN, India)

  • Mirror Movements in extrapiramidal diseases

    A. Manin, S. Rodríguez-Quiroga, L. Piedrafita Vico, N. Larripa, L. Assante, J. Casen, T. Arakaki, N. Garretto (Buenos Aires, Argentina)

  • Mitochondrial DNA variants function as potential genetic risk factors for Parkinson disease

    X. Zhang, T. Li, Z.-F. Fan, B.-L. Hu, J.-H. Zhu (Wenzhou, China)

  • MitoQ and Reduced Glutathione Protects Against Dopamine Induced Brain Mitochondrial Electron Transport Chain Inhibition During Extended In Vitro Incubation: Involvement of Free Radicals and Quinone Products

    A. MAITI (Bengaluru, India)

  • Modeling Parkinson’s disease pathology by combined injection of fibrilar and monomeric α-synuclein in rat brain

    P. Thakur, L. Breger, M. Lundblad, O. Wan, B. Mattsson, K. Luk, V. Lee, J. Trojanowski, A. Björklund (Frankfurt, Germany)

  • Modulation of executive motor network after neurofeedback training in Parkinson’s disease

    N. Smulders, D. Mehler, L. Subramanian, D. Linden, J. Whittaker (Cardiff, United Kingdom)

  • More effective rTMS site for the freezing of gait in Parkinson’s disease

    S.Y. Kang, S.J. Kim (Hwaseong, Republic of Korea)

  • Morphometric changes in Parkinson’s disease manifesting freezing of gait

    S. Pietracupa, A. Suppa, N. Upadhyay, A. Zampogna, F. Di Biasio, G. Grillea, N. Modugno, G. Fabbrini, A. Berardelli, P. Pantano (Pozzilli, Italy)

  • Motor and Body Composition Variables by Parkinson’s Disease Staging

    L. LEANDRO, C. MOREIRA, H. TEIVE (Curitiba, Brazil)

  • Motor and non-motor symptoms in old-age onset Parkinson’s Disease patients

    M. Mendonça, T. Lampreia, R. Miguel, A. Caetano, R. Barbosa, P. Bugalho (Lisboa, Portugal)

  • Motor and Nonmotor clinical phenotype in LRRK2 Parkinson’s disease patients: a Case-control study

    L. Correia Guedes, R. Bouça, N. Gonçalves, T. Soares, D. Abreu, M. Fabbri, M. Coelho, M.M. Rosa, M. Quadri, T. Outeiro, C. Sampaio, V. Bonifati, J. Ferreira (Lisbon, Portugal)

  • Motor complications and others of therapy but not non-motor symptoms burden predict short-term mortality in non-demented Parkinson´s disease patients

    D. Santos García, E. Suárez Castro, I. Expósito Ruíz, C. Tuñas Gesto, M. Aneiros Díaz, M. López Fernández, T. de Deus, D. Núñez Arias, J. Ernández (Ferrol, Spain)

  • Motor dysfunctions in rats following repeated exposure to stress on the neurotoxicity of lambda-cyhalothrin

    R. Shukla, R. Gupta, A. Pant, V. Khanna (Lucknow, India)

  • Motor effects and safety of IPX203, an investigational extended-release formulation of carbidopa-levodopa, in advanced Parkinson’s disease: A single-dose study

    M. Stacy, V. Biton, J. Aldred, A. Ellenbogen, R. Rubens, N. Modi, A. Mittur, S. Khanna, S. Gupta (Durham, NC, USA)

  • Motor effects induced by D1- or D2-like receptor agonists in experimental parkinsonism.

    L. Andreoli, C. Alcacer, I. Sebastianutto, A. Cenci Nilsson (Lund, Sweden)

  • Motor Heterogeneity in Parkinson’s Disease: A Bayesian Perspective

    A. Johnson, A. Loftus, N. Gasson, B. Lawrence, M. Thomas, R. Bucks (Perth, Australia)

  • Motor imagery increases imitation of hand movements in Parkinson’s disease

    J. Bek, E. Gowen, S. Vogt, T. Crawford, E. Poliakoff (Manchester, United Kingdom)

  • Motor performance measured with the UPDRS in PD patientswith varying degrees of smell loss

    c. cox, A. Kahttab, K. Amar (Bournemouth. Dorset, United Kingdom)

  • Motor resonance in Parkinson’s disease: Effects of observed actions on behaviour

    E. Poliakoff, J. Bek, S. Vogt, T. Crawford, E. Gowen (Manchester, United Kingdom)

  • Motor stress elicits dystonia-like movements in a pharmacological mouse model for Rapid-Onset Dystonia-Parkinsonism (DYT12)

    L. Rauschenberger, J. Volkmann, C.W. Ip (Wuerzburg, Germany)

  • Movement Disorder Society – Clinical Diagnostic Criteria for Progressive Supranuclear Palsy

    G. Höglinger, G. Respondek, M. Stamelou, C. Kurz, K. Josephs, A. Lang, B. Mollenhauer, U. Müller, C. Nilsson, J. Whitwell, A. Boxer, L. Golbe, I. Litvan (Munich, Germany)

  • Movement disorder specialists’ determination of eligibility for device aided treatment in advanced Parkinson’s disease: Results from the OBSERVE-PD study

    A. Fasano, K. Seppi, V.SC. Fung, J.C. Parra, L. Bergmann, A. Yegin, K. Sail, Y. Jalundhwala, K. Onuk (Toronto, ON, Canada)

  • Movement Disorders and Clinical Progression in Spinocerebellar Ataxias

    P.-H. Kuo, J. Wang, K. Figueroa, S. Pulst, S. Perlman, G. Wilmot, C. Gomez, J. Schmahmann, H. Paulson, V. Shakkottai, S. Ying, T. Zesiewicz, K. Bushara, M. Geschwind, G. Xia, S. Subramony, T. Ashizawa, S.-H. Kuo (Hualien, Taiwan)

  • Movement disorders caused by benign brain tumor

    A.M. Magnerou, P.E. Sounga Bandzouzi, H.F. Ngoungoure, M.M. Ndiaye (DAKAR, Senegal)

  • Movement Disorders in Demyelinating Diseases: a retrospective review from a tertiary academic center.

    G. Suarez-Cedeno, M. Raja (Houston, TX, USA)

  • Movement Disorders secondary to Spinal Cord Demyelination: an Evolving Spectrum

    H. Abboud, H. Fernandez, X.X. Yu, M. Mealy, M. Levy, J. Cohen (Cleveland, OH, USA)

  • Movement Disorders Tele-Education program for undergraduate medical students in low-middle, high income countries.

    E. Cubo, J. Doumbe, E. Lopez, C. Kuate, E. Gatto, B. Epundugu, G. Persi, G. Lopez (Burgos, Spain)

  • Moxibustion for Parkinson’s disease: a systematic review of randomized controlled trials

    T.-H. Kim, S. Kwon, W.-S. Jung, S.-K. Moon, C.-N. Ko, S.-Y. Cho, C.-Y. Jun, S.-H. Lee, K.-H. Cho (Seoul, Republic of Korea)

  • MRI-based Brain Networks of Perfusion and Structural Abnormalities in Patients with Cerebellar Variant of Multiple System Atrophy

    P. Wu, S. Peng, J. Ge, J. Wang, D. Eidelberg, C. Zuo, Y. Ma (Shanghai, China)

  • Multi-modal retention in a phase III clinical trial in early Parkinson disease (STEADY-PD III)

    B. Greco, T. Simuni, J. Denmark, S. Henderson, J. Lowell, S. Sharma, C. Tarolli, D. Young, K. Biglan (Rochester, NY, USA)

  • Multicenter Validation of Disease- related Parkinson’s disease pattern with Resting State functional MRI

    K. Schindlbeck, A. Vo, Y. Ma, S. Peng, K. Poston, H. Hurtig, N. Dahodwala, D. Eidelberg (Manhasset, NY, USA)

  • Multidisciplinary intensive outpatient rehabilitation program for patients with advanced Parkinson’s disease: feasibility and primary proof of concept

    T. Gurevich, T. GAIL, n. choen, o. KADURRI, L. SHTRAIFLER, I. BADICHI, N. RIPS CASSERI (tel aviv, Israel)

  • Multidisciplinary Parkinson rehabilitation delays nursing home admission and is cost-effective.

    E. Steendam-Oldekamp, W. Rutgers, T. van Laar (Groningen, Netherlands)

  • Multimodal biomarkers as predictors of cognitive decline in Parkinson’s Disease

    T. Tropea, J. Berlyand, J. McBride, J. Doshi, C. Davatzikos, L. Shaw, S. Xie, J. Trojanowski, D. Weintraub, A. Chen-Plotkin (Philadelphia, PA, USA)

  • Multiple modality biomarker prediction of cognitive impairment in prospectively followed de novo Parkinson disease

    D. Weintraub (Philadelphia, PA, USA)

  • Multiple myeloma induced parkinsonism

    H. DS, V. Paramanandam, P.c. N (Chennai, India)

  • Multiple Neural Networks dysfunction in Primary Blepharospasm: An Independent Components Analysis Study

    X. Huang, Z.-h. Liang, M.-r. Zhu (Dalian, China)

  • Multivariate analysis of writer`s cramp: a study with advanced multi-channel microelectrode recording system

    V. Rama raju, R. Borgohain (Hyderabad, India)

  • Mutant DNAJC13 modulates accumulation and toxicity of alpha-synuclein through altered endosomal trafficking in cell and fly models of Parkinson’s disease

    T. Hasegawa, S. Yoshida, M. Suzuki, J. Kobayashi, N. Sugeno, K. Sekiguchi, M. Edura, A. Kikuchi, A. Takeda, Y. Nagai, M. Aoki (Sendai, Japan)

  • Mutational analysis of COQ2 in Chinese patients with multiple-system atrophy

    J. Zhang, Y. Hao, Y. Chen, M. Ding, X. Zhang, W. Gu (Beijing, China)

  • Myoclonus in adult onset Huntington’s disease

    S. McAllister, S. Shipley, J. Shah, R. Fekete (New York, NY, USA)

  • Myoclonus in the Elderly: Retrospective Analysis of Clinical and Electrophysiological characteristics of patients referred to an electrophysiology laboratory

    M. Kiziltan, A. Gunduz, M. Tutuncu, U. Uygunoglu, A. Sifoglu, S. Ertan, H. Apaydin, M. Bozluolcay, S. Saip, G. Kiziltan (Istanbul, Turkey)

  • Myths and Misconceptions Regarding Huntington’s Disease in Peru

    A. Vishnevetsky, M. Illanes-Manrique, M. Inca-Martinez, M. Cornejo-Olivas (Philadelphia, PA, USA)

Jump to:  View All • a b c d e f g h i j k l [m] n o p q r s t u v w x y z

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Welcome to the MDS Abstracts Site
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley